Assessment of the Clinical and Medico-economic Impact of SinnoTest® in Patients With Rheumatoid Arthritis

Inclusion Criteria: * Patients with Rheumatoid Arthritis defined according to ACR/EULAR 2010 or ACR 1987 criteria. * Patients in failure (patient insufficiently responding to anti-TNF treatment DAS28 \> 3.2 whether related to primary biotherapy failure, loss of efficacy (loss of response) or adverse event) of a first bDMARD of the anti-TNF family (Adalimumab, Infliximab, Etanercept, Certolizumab or Golimumab). * Stability of synthetic fund processing for 3 months. * Corticosteroids ≤ 0.1 mg/kg/day without cortisone assault within 3 months. * Effective contraception for patients with reproductive capacity (oral contraceptive, intrauterine device, implant, surgical sterilization or abstinence). * Patients who have dated and signed the consent form for the trial. * Patients affiliated to a social security system. Exclusion Criteria: * Contraindication to at least one of the following bDMARDs: Rituximab and/or Abatacept and/or Adalimumab. * Scheduled surgical intervention during the trial. * Difficulties in understanding the French language. * Cognitive function disorders (dementia such as Alzheimer's, etc.). * Patients who cannot be followed up at 12 months. * Psycho-social instability incompatible with regular follow-up (homelessness, addictive behavior, a history of psychiatric pathology or any other comorbidity that would make free and informed consent impossible or limit adherence to the protocol). * Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant woman, parturient, breastfeeding mother, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure). * Patients currently participating in other clinical research or who participated in a clinical trial within one month prior to inclusion.